window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 18, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

clinical trial

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Grifols completes Phase 3 SPARTA study of Prolastin-C in alpha-1 emphysema

    Grifols has completed patient follow-up in its Phase 3 SPARTA [...]

    August 11, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development

    FDA allows Medicus Pharma to start SkinJect study in patients with Gorlin Syndrome

    Medicus Pharma has received FDA clearance to begin a Phase [...]

    July 28, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    ViiV Healthcare HIV regimen Dovato non-inferior to Biktarvy in Phase 3b study

    ViiV Healthcare’s two-drug HIV regimen Dovato was non-inferior to the [...]

    July 28, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    CAMP4 wins Australian clearance to begin Phase 1/2 trial of SYNGAP1 therapy

    CAMP4 Therapeutics has received Australian regulatory and ethics clearance to [...]

    July 27, 2026
  • Advanced Therapies,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma

    Enterome Phase 1/2 data show EO2463-induced CD8 T-cell expansion was [...]

    July 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer

    Telix has dosed the first patient in a Phase 3 [...]

    July 22, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Medicus receives FDA feedback and IRB approval for Teverelix Phase 2 urinary retention trial

    Medicus Pharma has received positive feedback from FDA and central [...]

    July 20, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data

    Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]

    July 14, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Q32 Bio reports positive Phase 2 alopecia areata trial results for bempikibart

    Q32 Bio has reported positive 36-week Phase 2 data showing [...]

    July 13, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg Pharma doses first patient in POLB 001 trial to prevent cytokine release syndrome

    Poolbeg Pharma has dosed the first patient in a clinical [...]

    July 13, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CN Bio wins Innovate UK grant to develop human-relevant drug testing workflow
    Categories: Digital & Data, Drug Discovery & Development, Manufacturing & Supply Chain, Research & Development
  • FDA grants Priority Review to Belite Bio’s tinlarebant for Stargardt disease
    Categories: Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Skylark Bio doses first patient in Phase 1/2 trial for GJB2-related deafness
    Categories: Advanced Therapies, Clinical & Regulatory, Genomics and sequencing, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top